Glenmark to outlicense one molecule in FY10

24 Dec 2009 Evaluate

Glenmark Pharmaceuticals is looking to out-license at least one molecule in fiscal 2010, probably Melogliptin. It is renegotiating a deal for the diabetes drug and is seeking a tie-up for anti-asthma drug Oglemilast for the European market. It is also looking to outlicense phase 2-b trials Oglemilast.

 

Outlicensing of Melogliptin and launch of Crofelmer (for HIV-related diarrhoea), which is a phase 3 candidate, are focus areas for Glenmark. A successful launch of Crofelmer can add $20-25 million annually to the company's net profit.

 

Meanwhile, Glenmark expects to launch Crofelmer across the world by the end of the next fiscal. The company is expecting sales of $80 million in the next 2-3 years as it will price the product at a premium to the currently available treatment options.

crackcrack

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×